ProQR Therapeutics N.V. (FRA:0PQ)

Germany · Delayed Price · Currency is EUR

1.783

+0.103 (6.13%)

Last updated: Dec 5, 2025, 8:02 AM CET

-48.47% (1Y)

Market Cap	189.26M
Revenue (ttm)	16.07M
Net Income (ttm)	-42.57M
Shares Out	n/a
EPS (ttm)	-0.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	60
Open	1.783
Previous Close	1.680
Day's Range	1.783 - 1.783
52-Week Range	0.955 - 3.388
Beta	n/a
RSI	41.10
Earnings Date	Mar 13, 2026

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-ass... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2012

Employees 166

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 0PQ

Full Company Profile

Financial Performance

In 2024, ProQR Therapeutics's revenue was 19.55 million, an increase of 196.41% compared to the previous year's 6.59 million. Losses were -27.76 million, -1.27% less than in 2023.

Financial Statements

News

There is no news available yet.